Ask AI

Heart Failure Decision Lab: An Expert Masterclass in Integrating Biology, Diagnostics, and Evidence-Based Therapy

Video
This activity is available for 0.75 CME/CE credit(s).

Released: October 29, 2026

Expiration: October 28, 2027

See Activity Collection

It is essential that healthcare professionals recognize and connect heart failure biology across the ejection fraction spectrum, which can be done with early evaluation, risk stratification, and phenotyping. Watch this on-demand webcast to learn best practices in diagnosing and treating heart failure, including strategies for translating the latest evidence into your clinical practice and providing guideline-directed medical therapy as indicated.

Heart failure decision lab webcast

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with heart failure do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 68-yr-old woman with obesity, HTN, T2D, and AF has progressive exertional dyspnea. LVEF is 58%, LV mass is increased, left atrial volume is enlarged, and E/e′ is elevated. NT-proBNP is moderately elevated. Which interpretation best informs her heart failure risk assessment?

4.

A 66-yr-old woman with obesity, hypertension, and T2D reports progressive exertional dyspnea. LVEF is 60%, NT-proBNP is only mildly elevated, and resting echocardiography shows left atrial enlargement with borderline E/e′. Her HFA-PEFF score is intermediate. Which approach would best clarify the diagnosis and phenotype?

5.

A 62-yr-old man with newly diagnosed HFrEF (LVEF 30%), T2D, and CKD stage 3a is euvolemic after treatment for congestion. He is taking low-dose sacubitril/valsartan and carvedilol.
BP is 104/66 mm Hg, HR 68 beats/min, eGFR 48 mL/min/1.73 m2, and K⁺ 4.7 mEq/L. Which strategy best optimizes his GDMT?